Nucleic Acid Therapeutics Market to Reach US$ 14.42 Billion by 2032 at 10.9% CAGR; North America Leads with 42% Share

The Global Nucleic Acid Therapeutics Market reached US$ 5.64 billion in 2024 and is expected to reach US$ 14.42 billion by 2032, growing at a CAGR of 10.9% during the forecast period 2025-2032. Market growth is driven by increasing research and development in gene- and RNA-based therapies, rising prevalence of genetic and rare diseases, and growing adoption of advanced nucleic acid platforms for therapeutic applications.

Nucleic acid therapeutics involve the use of DNA, RNA, or modified nucleic acids to correct genetic mutations, modulate gene expression, or inhibit disease-causing proteins. Key approaches include gene therapy, RNA interference (RNAi), antisense oligonucleotides (ASOs), and mRNA-based therapies, targeting conditions such as cancer, neurological disorders, and inherited genetic diseases. Advances in delivery technologies, expanding clinical pipelines, and regulatory support are further accelerating the global market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/nucleic-acid-therapeutics-market?sai-v

The Nucleic Acid Therapeutics Market refers to the global industry focused on the development, production, and commercialization of therapies that use nucleic acids, such as DNA, RNA, or antisense oligonucleotides, to treat or prevent diseases at the genetic or molecular level.

Key Developments
✅ January 2026: In North America, advances in delivery technologies, including lipid nanoparticles and targeted vectors, enhanced clinical progress for nucleic acid therapies such as siRNA, antisense oligonucleotides, and mRNA therapeutics, expanding treatment possibilities across rare genetic disorders and oncology.

✅ December 2025: In Europe, regulatory agencies provided updated guidance frameworks for nucleic acid therapeutics, supporting accelerated development pathways and harmonized assessment of safety and efficacy for novel modalities.

✅ November 2025: In Asia-Pacific, increasing investment in genomic medicine and biotechnology infrastructure boosted regional participation in global nucleic acid therapy trials, particularly in cardiovascular and metabolic disease applications.

✅ October 2025: In Latin America, partnerships between academic institutions and biopharma companies strengthened local translational research capabilities, enabling early-stage development of nucleic acid-based candidates for infectious diseases and cancer.

✅ September 2025: In the Middle East, public-private collaborations expanded focus on nucleic acid therapy research programs, including efforts to develop regionally relevant therapeutics and build clinical trial capacity.

✅ August 2025: In Africa, pilot initiatives supported by international research consortia increased access to nucleic acid testing platforms and early translational research training, laying groundwork for future therapeutic development.

Mergers & Acquisitions
✅ January 2026: In North America, a major biopharmaceutical company acquired a nucleic acid delivery technology firm to strengthen its pipeline of RNA-based therapeutics and enhance delivery platforms for antisense oligonucleotide and mRNA programs.

✅ December 2025: In Europe, a healthcare investment group acquired a specialty oligonucleotide synthesis and development services provider to expand its capabilities in supporting global nucleic acid therapeutic programs.

✅ November 2025: In Asia-Pacific, a regional biotechnology investor acquired a gene modulation and RNA analytics company to broaden its nucleic acid therapy research and support services across emerging markets.

Key Players
Ionis Pharmaceuticals | Alnylam Pharmaceuticals, Inc. | Gilead Sciences, Inc. | AstraZeneca | Sarepta Therapeutics, Inc. | Creative Biolabs | GSK plc | Novartis AG | BioNTech SE | Silence Therapeutics

Key Highlights
Alnylam Pharmaceuticals, Inc. holds 21.6% share, driven by its leadership in RNA interference (RNAi) therapeutics, multiple commercialized products, and strong clinical pipeline targeting rare and chronic diseases.

Ionis Pharmaceuticals holds 18.9% share, supported by its antisense oligonucleotide (ASO) platform, extensive partner network, and broad pipeline across neurological and cardiometabolic indications.

Gilead Sciences, Inc. holds 14.7% share, benefiting from strategic investments in RNA-based therapies, strong commercialization capabilities, and integration of advanced nucleic acid platforms.

AstraZeneca holds 12.5% share, driven by partnerships and internal development of RNA therapeutics, with focus on oncology, cardiovascular, and respiratory diseases.

Sarepta Therapeutics, Inc. holds 10.2% share, supported by exon-skipping RNA therapies and strong positioning in rare neuromuscular disorders.

Novartis AG holds 8.6% share, leveraging its advanced therapeutics pipeline, gene and RNA therapy research, and global development infrastructure.

BioNTech SE holds 6.1% share, driven by mRNA platform innovation and expanding RNA-based applications beyond vaccines into oncology and immunotherapy.

GSK plc holds 4.9% share, focused on RNA-targeted drug discovery and strategic collaborations in genetic medicine.

Silence Therapeutics holds 2.7% share, specializing in siRNA discovery and delivery technologies for rare and metabolic diseases.

Creative Biolabs holds 1.8% share, contributing through research services, custom RNA tools, and early-stage therapeutic development support.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=nucleic-acid-therapeutics-market?sai-v

Market Drivers
- Rapid advancements in biotechnology and molecular medicine enabling development of nucleic acid-based therapies such as siRNA, antisense oligonucleotides (ASOs), mRNA therapeutics, and gene editing.

- Growing prevalence of genetic, rare, and infectious diseases driving demand for precision treatment modalities.

- Increasing research and development investments by pharmaceutical and biotech companies in nucleic acid therapeutics pipelines.

- Expansion of funding and supportive regulatory frameworks for innovative therapies with breakthrough potential.

- Improvements in delivery technologies (e.g., lipid nanoparticles, conjugates) enhancing stability, targeting, and clinical efficacy of nucleic acid drugs.

Industry Developments
- Launch and clinical progression of novel mRNA-based therapeutics and vaccines beyond COVID-19, targeting oncology, rare diseases, and metabolic disorders.

- Strategic collaborations between biopharmaceutical firms, academic institutions, and contract development/manufacturing organizations (CDMOs) to accelerate research and scale production.

- Advancements in gene editing platforms (e.g., CRISPR/Cas systems) integrated with nucleic acid therapeutic approaches.

- Expansion of delivery platform innovations to improve tissue targeting and reduce off-target effects.

- Increased regulatory approvals and expanded clinical trial activity across diverse therapeutic indications.

Regional Insights
North America - 42% share: "Driven by strong biotech ecosystem, extensive R&D investments, high clinical trial activity, and early adoption of nucleic acid therapies."

Europe - 26% share: "Supported by collaborative research networks, growing investment in advanced therapeutics, and expanding clinical development landscape."

Asia Pacific - 24% share: "Fueled by rising healthcare expenditure, expanding biotechnology sector, increasing clinical research activities, and supportive healthcare initiatives."

Latin America - 5% share: "Driven by growing awareness of genomic medicine, expanding research capabilities, and improving healthcare infrastructure."

Middle East & Africa - 3% share: "Supported by developing biotechnology ecosystems, gradual adoption of advanced therapeutics, and increased healthcare investments."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/nucleic-acid-therapeutics-market?sai-v
Key Segments
By Type
Antisense oligonucleotides account for a significant share, driven by their proven efficacy in treating genetic and rare diseases. Small interfering RNA (siRNA) represents a substantial segment, supported by advancements in RNA interference technologies and delivery systems. Messenger RNA (mRNA) therapeutics are a fast-growing segment, driven by success in vaccine development and expanding therapeutic applications. Aptamers and other nucleic acid-based therapeutics contribute to market growth through niche and emerging treatment approaches.

By Application
Genetic disorders dominate the application segment, driven by the ability of nucleic acid therapeutics to target disease at the molecular level. Oncology represents a major segment, supported by growing adoption of RNA- and DNA-based therapies for targeted cancer treatment. Infectious diseases hold a significant share, driven by continued development of nucleic acid-based antivirals and vaccines. Cardiovascular and neurological disorders contribute steadily, supported by ongoing research and expanding clinical pipelines. Other applications support market growth through emerging therapeutic indications.



Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.